Bio Techne Revenue Growth Rates (TECH), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Bio techne Corp  (NASDAQ: TECH)
 

TECH's Revenue Growth by Quarter and Year

Bio Techne's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/TECH/growth
https://api.csimarket.com/api/v1/companies/TECH/fundamentals
https://api.csimarket.com/api/v1/companies/TECH/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
TECH Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter June -
3rd Quarter March -
2nd Quarter December -
1st Quarter September 299.71
FY 299.71

TECHs Annual Revenue
Bio Techne's Revenue in the fiscal year 2026 $ 1,215.04 millions
Bio Techne's Revenue in the fiscal year 2025 $ 1,219.27 millions
Bio Techne's Revenue in the fiscal year 2024 $ 1,158.73 millions
Bio Techne's Revenue in the fiscal year 2023 $ 1,135.82 millions
Bio Techne's Revenue in the fiscal year 2022 $ 1,105.60 millions




TECH Revenue first quarter 2026 Y/Y Growth Comment
Bio techne Corp reported Revenue growth of 4.75% year on year in the first quarter 2026, to $ 299.71 millions, this is lower than Bio Techne Corp's recent average Revenue increase of 10.41%.

Looking into first quarter 2026 results within Biotechnology & Pharmaceuticals industry 43 other companies have achieved higher Revenue growth. While Bio Techne Corp' s Revenue increase of 4.75% ranks overall at the positon no. 2725 in the first quarter 2026.


TECH Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter June -
3rd Quarter March -
2nd Quarter December -
1st Quarter September 4.75 %
FY   -

Financial Statements
Bio Techne's first quarter 2026 Revenue $ 299.71 millions TECH's Income Statement
Bio Techne's first quarter 2025 Revenue $ 286.11 millions Quarterly TECH's Income Statement


TECH Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter June -
3rd Quarter March -
2nd Quarter December -
1st Quarter September -6.69 %
FY (Year on Year)   -


Back to TECH Growth rate Comparisons >> Back to TECH Growth rate Comparisons >>


Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #44
Healthcare Sector #386
Overall #2725

Revenue Y/Y Growth Statistics
High Average Low
47.31 % 10.41 % -9.44 %
(Sep 30 2021)   (Jun 30 2013)
Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #44
Healthcare Sector #386
Overall #2725
Revenue Y/Y Growth Statistics
High Average Low
47.31 % 10.41 % -9.44 %
(Sep 30 2021)   (Jun 30 2013)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Bio Techne's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
33.65 % 2.7 % -23.88 %
(Sep 30 2011)  


TECH's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Bio Techne Corp disclosed decline in Revenue from the fourth quarter by -6.69% to $ 299.71 millions, from $ 321.19 millions achived in the previous reporting period.

But that's not important problem, as Bio Techne's Revenue generally seem to plunge in this quarter.

Within Biotechnology & Pharmaceuticals industry 25 other companies have achieved higher Revenue quarter on quarter growth. While Bio Techne's Revenue growth quarter on quarter, overall rank is 1348.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #26
Healthcare Sector #188
Overall #1348
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #26
Healthcare Sector #188
Overall #1348
Revenue Q/Q Growth Statistics
High Average Low
33.65 % 2.7 % -23.88 %
(Sep 30 2011)  


TECH's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Bio Techne Corp disclosed decline in Revenue from the fourth quarter by -6.69% to $ 299.71 millions, from $ 321.19 millions achived in the previous reporting period.

But that's not important problem, as Bio Techne's Revenue generally seem to plunge in this quarter.

Within Biotechnology & Pharmaceuticals industry 25 other companies have achieved higher Revenue quarter on quarter growth. While Bio Techne's Revenue growth quarter on quarter, overall rank is 1348.


Bio Techne's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 1,213.87
Y / Y Revenue Growth (TTM) -0.44 %
Year on Year Revenue Growth Overall Ranking # 2029
Seqeuential Revenue Change (TTM) 0.28 %
Seq. Revenue Growth (TTM) Overall Ranking # 2471


Cumulative Revenue growth Comment
For the 12 months ended Jun 30 2026 Bio Techne reported a decrease in Revenue by -0.44% year on year, to $1,214 millions, compare to the 0.24% growth at Mar 31 2026.

In the Healthcare sector 305 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1335 to 2029.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 38
Healthcare Sector # 306
Overall # 2029

Revenue TTM Y/Y Growth Statistics
High Average Low
29.61 %
 11.17 %
-1.27 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 38
Sector # 361
S&P 500 # 2471
Cumulative Revenue growth Comment
For the 12 months ended Jun 30 2026 Bio Techne reported a decrease in Revenue by -0.44% year on year, to $1,214 millions, compare to the 0.24% growth at Mar 31 2026.

In the Healthcare sector 305 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1335 to 2029.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 38
Healthcare Sector # 306
Overall # 2029

Revenue TTM Y/Y Growth Statistics
High Average Low
29.61 %
11.17 %
-1.27 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 38
Sector # 361
S&P 500 # 2471




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
TECH's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decrease for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Fulgent Genetics Inc 8.26%$ 8.262 millions
Amphastar Pharmaceuticals Inc 8.22%$ 8.219 millions
Ultragenyx Pharmaceutical Inc 8.17%$ 8.170 millions
Baxter International Inc 8.08%$ 8.078 millions
Tactile Systems Technology Inc 8.07%$ 8.067 millions
Iqvia Holdings Inc 8.00%$ 8.000 millions
Exagen Inc 7.86%$ 7.859 millions
Gyre Therapeutics Inc 7.75%$ 7.754 millions
Stryker Corp7.64%$ 7.644 millions
Bausch and Lomb Corp7.34%$ 7.338 millions
Addus Homecare Corp7.19%$ 7.193 millions
Pacific Biosciences Of California Inc 7.03%$ 7.026 millions
Bristol myers Squibb Company6.93%$ 6.930 millions
Labcorp Holdings Inc 6.92%$ 6.917 millions
Gilead Sciences Inc 6.83%$ 6.835 millions
Arcturus Therapeutics Holdings Inc 6.68%$ 6.682 millions
National Healthcare Corp6.61%$ 6.614 millions
Tenet Healthcare Corp6.47%$ 6.466 millions
Phibro Animal Health Corporation6.32%$ 6.320 millions
Mettler toledo International Inc 6.27%$ 6.273 millions
Agilon Health Inc 5.86%$ 5.864 millions
Johnson and Johnson5.86%$ 5.860 millions
Stoke Therapeutics Inc 5.86%$ 5.860 millions
Genedx Holdings Corp 5.64%$ 5.642 millions
Adma Biologics Inc 5.59%$ 5.595 millions
Innoviva Inc 5.55%$ 5.551 millions
Universal Health Services Inc 5.30%$ 5.297 millions
Acadia Healthcare Company Inc 5.14%$ 5.136 millions
Lumexa Imaging Holdings Inc 5.03%$ 5.032 millions
Bio techne Corp4.75%$ 4.753 millions


About Bio Techne Revenue Growth Rates (TECH), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Bio Techne Corp (CIK 842023).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-26-123907
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Bio Techne Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.